Pivotal Therapeutics engages Kilmer Lucas for cross-border investor relations

WOODBRIDGE, ON, June 11, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that it retained Kilmer Lucas Inc. to provide it with Canadian and U.S. investor relations and strategic advisory services.

"As we begin to fully execute our growth strategy, we are confident that Kilmer Lucas is the right partner to help us communicate our progress to a broader audience," said Mr. Eugene Bortoluzzi, Pivotal's CEO and CFO.  "We are particularly pleased that Stephen Kilmer and Leonard Zehr will personally be managing and executing our cross-border investor relations and financial communications program.  Before founding Kilmer Lucas, Stephen was a cross-border IR pioneer – managing the investor and public relations functions for two TSX/NASDAQ dual-listed Canadian-based healthcare companies. Prior to joining Kilmer Lucas, Leonard amassed 36 years of experience as a financial journalist, editor and manager with The Wall Street Journal and Dow Jones News Service, and The Globe and Mail's Report on Business, where he pioneered the development and launch of the newspaper's Money & Markets section in the early 1990s.  Most recently, he was Canada's leading biotechnology and healthcare writer, as well as the author of a highly popular stock market blog on globeandmail.com."

Mr. Kilmer commented, "The senior management team at Pivotal has a strong record of accomplishment in building shareholder value.  That, combined with Pivotal's unique positioning at the forefront of the emerging medical foods industry, provides the foundation for a great investment story, and we are excited that the Company has chosen us to help tell it.  Through the provision of a full range of investor relations and financial communications services, our primary goals will be to assist Pivotal in achieving a fair and sustainable market valuation and to enhancing the reputation that the Company carries in the minds of investors, analysts and members of the media."

About Kilmer Lucas Inc.

Kilmer Lucas combines a healthcare industry focus with a global reach.  Working directly from our offices in Toronto, New York and San Francisco, and through a carefully assembled affiliate network that includes seasoned professionals based in Israel, Asia and Europe, we help our clients to successfully navigate and penetrate the capital markets and media both at home and abroad.  More information about the firm can be found at www.kilmerlucas.com.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF; CSE:PVO), specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN® is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN® is a patented product available for sale and distribution in Canada.

About VASCAZEN®

VASCAZEN® is currently available in the U.S. as a prescription only Medical Food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients. VASCAZEN® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both U.S. and foreign patents.

VASCAZEN® has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile.   VASCAZEN®'s results were achieved with a dose of 3 grams of EPA and DHA per day of a prescription grade, high purity Omega-3.

Disclosure Notice
The information contained in this document is as of June 11, 2014. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSE listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.

SOURCE Pivotal Therapeutics Inc.



RELATED LINKS
www.pivotaltherapeutics.us

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.